BIONET Corp. (TPEX:1784)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
66.30
+0.80 (1.22%)
Jun 3, 2026, 1:30 PM CST
Market Cap3.34B -12.3%
Revenue (ttm)1.26B +3.6%
Net Income48.78M -36.3%
EPS0.97 -35.8%
Shares Out 50.31M
PE Ratio68.33
Forward PEn/a
Dividend1.42 (2.16%)
Ex-Dividend DateOct 1, 2026
Volume178,753
Open66.60
Previous Close65.50
Day's Range65.50 - 67.00
52-Week Range63.40 - 118.00
Beta0.47
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About BIONET

BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products; and Exosome, a cell-free therapy. The company was founded in 1989 and is... [Read more]

Sector Healthcare
Founded 1989
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 1784
Full Company Profile

Financial Performance

In 2025, BIONET's revenue was 1.24 billion, an increase of 1.19% compared to the previous year's 1.22 billion. Earnings were 51.43 million, a decrease of -38.56%.

Financial Statements